An observational study on the therapeutic effects of GLP-1 receptor agonists and patients' dietary behavior patterns in clinical practice

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1041250212

Enrollment

180

Registered

2026-03-23

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes diabetes

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who are judged by their physicians to be eligible for GLP-1 receptor agonists. In addition, patients who understand the purpose of the study and have given written consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have difficulty in following the instructions of the principal investigator or sub-investigator 2) Patients who are judged by the principal investigator or sub-investigator to be unsuitable for this study

Design outcomes

Primary

Measure	Time frame
Change in HbA1c from baseline to 52 weeks after treatment initiation, stratified by baseline food preference and eating behavior.	—

Secondary

Measure	Time frame
Stratified by baseline food preference and eating behavior: Proportion achieving target HbA1c at 52 weeks Proportion achieving HbA1c <7.0% at 52 weeks Change in body weight from baseline to 52 weeks Change in body composition from baseline to 52 weeks Change in handgrip strength from baseline to 52 weeks Change in total energy intake and macronutrient intake (FFQ) from baseline to 52 weeks Change in urinary albumin (or urinary protein in patients with diabetic nephropathy stage 3 or higher) from baseline to 52 weeks	—

Measure

Time frame

Stratified by baseline food preference and eating behavior: Proportion achieving target HbA1c at 52 weeks Proportion achieving HbA1c <7.0% at 52 weeks Change in body weight from baseline to 52 weeks Change in body composition from baseline to 52 weeks Change in handgrip strength from baseline to 52 weeks Change in total energy intake and macronutrient intake (FFQ) from baseline to 52 weeks Change in urinary albumin (or urinary protein in patients with diabetic nephropathy stage 3 or higher) from baseline to 52 weeks

—

Contacts

Public ContactYuya Koide

Gifu University Hospital

xmndy633@yahoo.co.jp+81-58-230-6000

Outcome results